Ali-Jackson Kamil 4

What Happened Ali-Jackson Kamil, a director of Rigel Pharmaceuticals, was granted 5,750 restricted stock units (reported as an award) on 2026-05-15. The reported acquisition price is $0.00 (standard for RSU grants); no cash changed hands on the grant date. These RSUs will convert to shares only upon vesting.

Key Details

• Transaction date: 2026-05-15; Filing date (Form 4): 2026-05-19 (filed within the two-business-day window).
• Transaction type/code: Award/Grant (A).
• Shares granted: 5,750 RSUs; reported acquisition value: $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: RSUs vest in full on the date prior to the company’s next Annual Meeting, subject to the reporting person’s continuous service on the Board (per footnote F1).

Context This was a compensation award (RSUs) for board service, not an open-market purchase or sale. RSU grants do not represent immediately tradable shares — they convert to stock only when they vest, and vesting is contingent on continued service. Awards are common for directors and should be viewed as compensation rather than a direct market signal.